Daily Endocrinology Research Analysis
Analyzed 79 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology studies stood out today: a translational PCOS study links gut microbiome depletion (Parabacteroides merdae) and elevated isoleucine to endometrial senescence and miscarriage; a UK Biobank analysis shows that combining body-fat percentage with waist circumference outperforms BMI for predicting cardiometabolic and kidney events; and an assay innovation enables isoform-specific growth hormone quantification (20/22 kDa) via immunocapture LC-MS/MS, refining acromegaly biomarker assessment.
Research Themes
- Microbiome–metabolite pathways driving reproductive endocrinology in PCOS
- Adiposity phenotyping beyond BMI for cardiometabolic risk stratification
- Analytical innovation in endocrine biomarkers (GH isoform LC-MS/MS)
Selected Articles
1. Microbial and Metabolic Correlates of Endometrial Dysfunction in Polycystic Ovary Syndrome: A Translational Study.
In women with PCOS, depletion of Parabacteroides merdae and elevated isoleucine correlated with higher miscarriage rates. Isoleucine induced senescence in human endometrial stromal cells, while restoring P. merdae in a PCOS rat model reduced isoleucine, ameliorated endometrial senescence, and lowered fetal resorption.
Impact: This study provides a novel microbiome–metabolite mechanism linking PCOS to endometrial dysfunction and miscarriage, with multi-system validation. It opens actionable translational avenues targeting P. merdae or branched-chain amino acid metabolism.
Clinical Implications: Potential for microbiota-based or amino acid–targeted interventions (e.g., P. merdae restoration, dietary BCAA modulation) to reduce miscarriage risk in PCOS; metabolite and microbial signatures may aid risk stratification.
Key Findings
- PCOS women had significantly higher miscarriage rates versus matched controls.
- Marked depletion of Parabacteroides merdae and elevated circulating isoleucine characterized PCOS.
- Exogenous isoleucine induced dose-dependent senescence in human endometrial stromal cells.
- Restoring P. merdae in a PCOS rat model reduced serum isoleucine, reversed endometrial senescence, and decreased fetal resorption.
Methodological Strengths
- Integrated prospective human cohort with metagenomics/metabolomics and matched controls.
- Mechanistic validation across in vitro human endometrial cells and in vivo PCOS rat model with microbial intervention.
Limitations
- Single-center cohort; causal inference in humans remains to be established.
- Translational gap from rodent model to human intervention and limited data on confounders (dietary BCAA intake).
Future Directions: Test microbiota or BCAA-targeted interventions (e.g., P. merdae supplementation, isoleucine reduction) in randomized trials to reduce miscarriage in PCOS; validate microbial-metabolite-endometrium signatures longitudinally.
OBJECTIVE: Women with polycystic ovary syndrome (PCOS) exhibit a substantially increased risk of miscarriage, yet the underlying mechanisms remain inadequately understood. This study aimed to investigate whether specific gut microbial dysbiosis and metabolic disturbance are associated with and may potentially contribute to endometrial dysfunction and adverse pregnancy outcomes in women with PCOS. DESIGN: Prospective cohort study integrated with mechanistic experiments. SETTING: Women's Hospital, School of Medicine, Zhejiang University, China (2022-2024). POPULATION: A total of 110 women with PCOS and 110 age- and body mass index-matched controls were enrolled. METHODS: We performed 16S rRNA and metagenomic sequencing of gut microbiota, with untargeted and targeted serum metabolomics. Functional validation was conducted using primary human endometrial stromal cells and a PCOS rat model intervened with Parabacteroides merdae (P. merdae) supplementation or faecal microbiota transplantation. MAIN OUTCOME MEASURES: Gut microbiota composition, serum metabolites, endometrial senescence markers, and pregnancy outcomes. RESULTS: Women with PCOS exhibited significantly higher miscarriage rates than controls, accompanied by a marked depletion of P. merdae abundance and elevated serum levels of branched-chain amino acids, particularly isoleucine. Exogenous isoleucine induced cellular senescence in human endometrial stromal cells in a dose-dependent manner. Restoration of P. merdae levels in the PCOS rat model resulted in decreased serum isoleucine levels, amelioration of the senescent endometrial phenotype, and reduction in the fetal resorption rate. CONCLUSIONS: These findings suggest that P. merdae depletion and the concurrent accumulation of isoleucine may be associated with endometrial senescence and elevated risk of miscarriage, suggesting the possible involvement of a gut microbiota-metabolite pathway in PCOS-related reproductive dysfunction. These results also provide a mechanistic basis for future translational investigations.
2. Adiposity-based obesity classification and cardiometabolic and kidney outcomes: a longitudinal UK Biobank analysis.
Across 489,311 UK Biobank participants, a body-fat-percentage plus waist-circumference classification produced stepwise risk stratification for T2D, CKD, and 3P-MACE and outperformed BMI, which missed many high-adiposity, high-risk individuals. One-third of the highest-risk group had normal-to-overweight BMI, underscoring BMI’s limitations.
Impact: Reframes obesity risk assessment by integrating adiposity quantity and distribution, offering superior prognostic value over BMI at population scale and with direct clinical applicability.
Clinical Implications: Incorporate BF% and waist circumference into routine risk stratification instead of relying on BMI alone; identify high-risk patients otherwise misclassified by BMI to target preventive cardiometabolic and kidney care.
Key Findings
- BF%-WC classification showed stepwise risk increases for T2D (HR 9.23), CKD (HR 2.27), and 3P-MACE (HR 1.63) versus the lowest-risk group.
- 32.6% of individuals in the highest BF%-WC risk group had BMI in the normal-to-overweight range, revealing BMI discordance.
- Overweight BMI category spanned all BF%-WC risk groups, limiting BMI’s discriminatory power.
Methodological Strengths
- Very large prospective cohort with median 13.1 years follow-up and hard outcomes.
- Consistent associations across endpoints with age/sex-adjusted Cox models and clear visualization of BMI discordance.
Limitations
- Observational design precludes causal inference.
- Potential measurement error in adiposity assessments and selection bias inherent to UK Biobank participants.
Future Directions: Evaluate BF%-WC-guided prevention strategies and thresholds across diverse populations; assess implementation in clinical workflows and guideline updates.
BACKGROUND: Obesity is commonly diagnosed using BMI, which does not capture total adiposity or fat distribution, as highlighted by the recent Lancet D&E Commission report. We assessed the prognostic value of an adiposity-based classification combining body fat percentage (BF%) and waist circumference (WC) in relation to cardiometabolic and kidney outcomes and evaluated its concordance with BMI. METHODS: We classified 489,311 UK Biobank participants into five risk groups (Groups 1-5) with increasingly adverse adiposity profiles based on BF%-WC. Associations with three-point major adverse cardiovascular events (3P-MACE), type 2 diabetes (T2D), and chronic kidney disease (CKD) were estimated using cumulative incidence and Cox PH models. Comparison with BMI categories was visualised with an alluvial plot. FINDINGS: Over a median 13.1 years (IQR 1.7), 24,778 (5.1%) participants experienced 3P-MACE, 30,376 (6.2%) had incident T2D, and 14,906 (3.0%) had incident CKD. The BF%-WC classification yielded stepwise risk stratification across endpoints. Compared to the reference Group 1, Group 5 had significantly higher risk: age- and sex-adjusted HR 9.23 (95% CI 8.70-9.83) for T2D, 2.27 (2.10-2.41) for CKD, and 1.63 (1.60-1.71) for 3P-MACE. Discordance with BMI was notable: 32.6% of individuals in the high-risk Group 5 had a BMI in the normal-to-overweight range, while the overweight category spanned all BF%-WC risk groups. INTERPRETATION: An adiposity-based classification integrating BF% and WC associates significantly with cardiometabolic and kidney outcomes and reveals discordance with BMI, reinforcing the Commission's framing of obesity as a disease driven by excess adiposity. FUNDING: SciLifeLab & Wallenberg DDLS Program; Knut and Alice Wallenberg Foundation; Swedish Research Council (2021-02623); Vinnova (2023-04234).
3. Quantitative analysis and clinical evaluation of 20- and 22-kDa growth hormone isoforms in somatotroph adenoma using immunocapture coupled with LC-MS/MS.
An immunocapture LC‑MS/MS assay achieved precise, simultaneous quantification of 20- and 22‑kDa GH isoforms with excellent analytical performance, and strong correlation to immunoassays despite systematic bias. Applied to 63 somatotroph adenoma patients, it promises improved biochemical remission assessment in GH disorders.
Impact: Provides an analytically specific tool to resolve GH isoforms, overcoming immunoassay cross-reactivity and enabling more accurate monitoring in acromegaly and related disorders.
Clinical Implications: Adoption of isoform-specific GH measurement could recalibrate immunoassay-derived cut-offs, refine remission criteria, and improve prognostic stratification in acromegaly management.
Key Findings
- Developed an immunocapture LC‑MS/MS method enabling simultaneous quantification of 20‑ and 22‑kDa GH1 without enzymatic digestion.
- Achieved linear ranges of 0.2–20.0 μg/L (20 kDa) and 1.0–100.0 μg/L (22 kDa), with intra/inter-assay CVs <10% and recoveries 95.0–102.5% after IS correction.
- Total GH by LC‑MS/MS was lower than immunoassay but strongly correlated, indicating systematic bias and improved specificity.
Methodological Strengths
- Immunocapture enrichment with stable isotope-labeled internal standard ensures specificity and quantitative accuracy.
- Simultaneous isoform quantification without proteolysis simplifies workflow and reduces analytical variability.
Limitations
- Clinical utility endpoints (e.g., remission thresholds, outcome prediction) require prospective validation.
- Systematic differences versus immunoassays necessitate harmonization before widespread clinical adoption.
Future Directions: Prospective studies to define isoform-aware remission thresholds and evaluate prognostic value; inter-laboratory harmonization and external quality assessment for clinical adoption.
OBJECTIVES: The 20- and 22-kDa isoforms of growth hormone 1 (GH1) play potentially distinct physiological and pathological roles, but their structural similarity makes quantification challenging. Conventional immunoassays lack sufficient specificity, highlighting the need for more precise analytical methods. METHODS: We developed a method combining immunocapture with liquid chromatography-tandem mass spectrometry (LC-MS/MS) for precise quantification of GH1 isoforms, with evaluation of sensitivity, accuracy, precision, and linearity. GH1 was isolated from 1-mL serum samples by immunocapture using antibody-coated magnetic beads, eluted, and quantified by LC-MS/MS. Stable isotope-labeled 22-kDa GH1 was used as an internal standard (IS). Clinical applicability was evaluated by analyzing serum GH1 isoforms in 63 patients with somatotroph adenoma. RESULTS: The assay demonstrated linear dynamic ranges of 0.2-20.0 μg/L for 20-kDa GH1 and 1.0-100.0 μg/L for 22-kDa GH1. Intra- and inter-assay coefficients of variation were <10 %, and recoveries ranged from 95.0 to 102.5 % after IS correction. Although total GH1 concentrations measured by LC-MS/MS were systematically lower than those obtained by immunoassay, the two methods were strongly correlated ( CONCLUSIONS: This immunocapture LC-MS/MS method enables simultaneous quantification of 20- and 22-kDa GH1 isoforms without enzymatic digestion. The implementation of this method may refine the assessment of biochemical remission and prognostic stratification in GH-related disorders.